Get started
JOHNSON & JOHNSONJOHNSON & JOHNSONJOHNSON & JOHNSON

JOHNSON & JOHNSON

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

JNJ chart


Full chart

Key facts today


Johnson & Johnson's Q1 revenue rose 2.4% to $21.89 billion, exceeding forecasts. Growth was driven by higher sales of cancer drug Darzalex and depression treatment Spravato.
Johnson & Johnson gained approval for TREMFYA to treat Crohn's disease and reported progress in its pipeline, including RYBREVANT data for lung cancer and a new trial for its robotic system, OTTAVA.
A Texas judge denied Johnson & Johnson's attempt to shift legal responsibility to a bankrupt subsidiary, allowing plaintiffs to proceed with claims in state courts.
Analyze the impactAnalyze the impact

JNJ upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪321.91 B‬ EUR
Dividend yield (indicated)
3.27%
Price to earnings Ratio (TTM)
25.78
Basic EPS (TTM)
5.64 EUR
Net income (FY)
‪13.59 B‬ EUR
Revenue (FY)
‪85.80 B‬ EUR
Shares float
‪2.41 B‬
Beta (1Y)
0.18

Employees


Employees (FY)
‪138.1 K‬
Change (1Y)
‪+6.2 K‬ +4.70%
Revenue / Employee (1Y)
‪621.27 K‬ EUR
Net income / Employee (1Y)
‪98.39 K‬ EUR

About Johnson & Johnson


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Joaquin Duato
Website
jnj.com
Headquarters
New Brunswick
Founded
1887
FIGI
BBG00GQ6S573
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

JNJ news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

JNJ highest yielding bonds


US478160CS1
JOHNSON&JOHN 20/50
Yield to maturity
7.02%
Maturity date
Sep 1, 2050
US478160CT9
JOHNSON&JOHN 20/60
Yield to maturity
6.95%
Maturity date
Sep 1, 2060
US478160CR3
JOHNSON&JOHN 20/40
Yield to maturity
6.46%
Maturity date
Sep 1, 2040
US478160CM4
JOHNSON & JOHNSON 17/48
Yield to maturity
6.30%
Maturity date
Jan 15, 2048
JNJJ
JOHNSON & JOHNSON 17/47
Yield to maturity
6.12%
Maturity date
Mar 3, 2047
US478160BV5
JOHNSON & JOHNSON 16/46
Yield to maturity
6.06%
Maturity date
Mar 1, 2046
US478160CL6
JOHNSON & JOHNSON 17/38
Yield to maturity
5.65%
Maturity date
Jan 15, 2038
JNJ4077469
Johnson & Johnson 4.5% 05-DEC-2043
Yield to maturity
5.52%
Maturity date
Dec 5, 2043
JNJ.GT
Johnson & Johnson 4.5% 01-SEP-2040
Yield to maturity
5.51%
Maturity date
Sep 1, 2040
US478160CX0
JOHNSON&JOHN 24/54
Yield to maturity
5.50%
Maturity date
Jun 1, 2054
US478160CF9
JOHNSON & JOHNSON 17/37
Yield to maturity
5.40%
Maturity date
Mar 3, 2037

See all JNJ bonds 

Sparks


Curated watchlists where JNJ is featured.

See all sparks 


Check out other big names from the same industry as JNJ.

Frequently Asked Questions


The current price of JNJ is 135.74 EUR — it has increased by 2.75% in the past 24 hours. Watch JOHNSON & JOHNSON stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange JOHNSON & JOHNSON stocks are traded under the ticker JNJ.
JNJ stock has risen by 0.28% compared to the previous week, the month change is a −10.27% fall, over the last year JOHNSON & JOHNSON has showed a −2.37% decrease.
We've gathered analysts' opinions on JOHNSON & JOHNSON future price: according to them, JNJ price has a max estimate of 162.87 EUR and a min estimate of 132.06 EUR. Watch JNJ chart and read a more detailed JOHNSON & JOHNSON stock forecast: see what analysts think of JOHNSON & JOHNSON and suggest that you do with its stocks.
JNJ reached its all-time high on Jul 12, 2022 with the price of 177.56 EUR, and its all-time low was 100.86 EUR and was reached on Mar 26, 2018. View more price dynamics on JNJ chart.
See other stocks reaching their highest and lowest prices.
JNJ stock is 0.87% volatile and has beta coefficient of 0.18. Track JOHNSON & JOHNSON stock price on the chart and check out the list of the most volatile stocks — is JOHNSON & JOHNSON there?
Today JOHNSON & JOHNSON has the market capitalization of ‪327.68 B‬, it has decreased by −2.78% over the last week.
Yes, you can track JOHNSON & JOHNSON financials in yearly and quarterly reports right on TradingView.
JOHNSON & JOHNSON is going to release the next earnings report on Apr 15, 2025. Keep track of upcoming events with our Earnings Calendar.
JNJ earnings for the last quarter are 1.97 EUR per share, whereas the estimation was 1.92 EUR resulting in a 2.43% surprise. The estimated earnings for the next quarter are 2.39 EUR per share. See more details about JOHNSON & JOHNSON earnings.
JOHNSON & JOHNSON revenue for the last quarter amounts to ‪21.75 B‬ EUR, despite the estimated figure of ‪21.67 B‬ EUR. In the next quarter, revenue is expected to reach ‪19.93 B‬ EUR.
JNJ net income for the last quarter is ‪3.31 B‬ EUR, while the quarter before that showed ‪2.42 B‬ EUR of net income which accounts for 36.98% change. Track more JOHNSON & JOHNSON financial stats to get the full picture.
Yes, JNJ dividends are paid quarterly. The last dividend per share was 1.19 EUR. As of today, Dividend Yield (TTM)% is 3.21%. Tracking JOHNSON & JOHNSON dividends might help you take more informed decisions.
JOHNSON & JOHNSON dividend yield was 3.40% in 2024, and payout ratio reached 84.80%. The year before the numbers were 3.00% and 84.93% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 15, 2025, the company has ‪138.1 K‬ employees. See our rating of the largest employees — is JOHNSON & JOHNSON on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JOHNSON & JOHNSON EBITDA is ‪27.27 B‬ EUR, and current EBITDA margin is 31.71%. See more stats in JOHNSON & JOHNSON financial statements.
Like other stocks, JNJ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JOHNSON & JOHNSON stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JOHNSON & JOHNSON technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JOHNSON & JOHNSON stock shows the strong sell signal. See more of JOHNSON & JOHNSON technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.